ABIOMED, Inc.
0.0 %
0.0 %
Yet to be announced
Company Overview
ABIOMED, Inc. is a medical device company that develops, manufactures, and markets advanced cardiac support technologies. Their main product is the Impella platform of heart pumps, which are used in high-risk cardiac procedures and for treating heart failure patients. The company's products help improve blood flow and provide circulatory support for patients in critical conditions.
Note: In December 2022, Johnson & Johnson completed its acquisition of ABIOMED, Inc. The company now operates as part of Johnson & Johnson's MedTech division.
Revenue Sources
PassBased on review of ABIOMED's revenue sources, their income is derived primarily from the sale of medical devices and related services that help save lives. These products and services are halal as they provide essential medical care. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2022 | $265.92m | $207.93m | - | - | 0.00% | 0.00% |
| June 30, 2022 | $277.15m | $211.1m | - | - | 0.00% | 0.00% |
| March 31, 2022 | $269.85m | $205.34m | - | - | 0.00% | 0.00% |
| Dec. 31, 2021 | $261.18m | $196.11m | - | - | 0.00% | 0.00% |
Analysis of the financial statements for the last four quarters shows zero interest income and zero interest expense. The company operated without reliance on interest-based financing or income during this period.
Operational Ethics
PassReview of ABIOMED's operations and partnerships shows no evidence of significant ongoing associations with entities involved in human rights violations. There are no current operations or R&D centers in Israel, and no proven material ties to the Chinese Communist Party have been identified.
Comments